Drug acetylation in breast cancer.

The acetylator phenotype was determined in 100 patients with breast cancer and 100 control female subjects using isoniazid. The proportion of fast acetylators in the breast cancer patients (43%) was not significantly different from the control group (43%). We conclude that acetylator phenotype is un...

Descripción completa

Detalles Bibliográficos
Autores principales: Webster, D. J., Flook, D., Jenkins, J., Hutchings, A., Routledge, P. A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247050/
https://www.ncbi.nlm.nih.gov/pubmed/2765373
_version_ 1782150898411110400
author Webster, D. J.
Flook, D.
Jenkins, J.
Hutchings, A.
Routledge, P. A.
author_facet Webster, D. J.
Flook, D.
Jenkins, J.
Hutchings, A.
Routledge, P. A.
author_sort Webster, D. J.
collection PubMed
description The acetylator phenotype was determined in 100 patients with breast cancer and 100 control female subjects using isoniazid. The proportion of fast acetylators in the breast cancer patients (43%) was not significantly different from the control group (43%). We conclude that acetylator phenotype is unlikely to be an important determinant of the risk of developing breast cancer. IMAGES:
format Text
id pubmed-2247050
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22470502009-09-10 Drug acetylation in breast cancer. Webster, D. J. Flook, D. Jenkins, J. Hutchings, A. Routledge, P. A. Br J Cancer Research Article The acetylator phenotype was determined in 100 patients with breast cancer and 100 control female subjects using isoniazid. The proportion of fast acetylators in the breast cancer patients (43%) was not significantly different from the control group (43%). We conclude that acetylator phenotype is unlikely to be an important determinant of the risk of developing breast cancer. IMAGES: Nature Publishing Group 1989-08 /pmc/articles/PMC2247050/ /pubmed/2765373 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Webster, D. J.
Flook, D.
Jenkins, J.
Hutchings, A.
Routledge, P. A.
Drug acetylation in breast cancer.
title Drug acetylation in breast cancer.
title_full Drug acetylation in breast cancer.
title_fullStr Drug acetylation in breast cancer.
title_full_unstemmed Drug acetylation in breast cancer.
title_short Drug acetylation in breast cancer.
title_sort drug acetylation in breast cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247050/
https://www.ncbi.nlm.nih.gov/pubmed/2765373
work_keys_str_mv AT websterdj drugacetylationinbreastcancer
AT flookd drugacetylationinbreastcancer
AT jenkinsj drugacetylationinbreastcancer
AT hutchingsa drugacetylationinbreastcancer
AT routledgepa drugacetylationinbreastcancer

Ejemplares similares